We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Applied Biosystems Introduces TaqMan® Drug Metabolism Assays
Product News

Applied Biosystems Introduces TaqMan® Drug Metabolism Assays

Applied Biosystems Introduces TaqMan® Drug Metabolism Assays
Product News

Applied Biosystems Introduces TaqMan® Drug Metabolism Assays


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Applied Biosystems Introduces TaqMan® Drug Metabolism Assays"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Applied Biosystems has announced the launch of TaqMan®, Drug Metabolism Genotyping Assays for the detection and study of polymorphisms in the drug metabolism pathway.

There are 2,000 assays for the detection of genetic variants in 220 genes that code for drug metabolism enzymes.

Gene variants or polymorphisms in drug metabolism enzymes are important pharmaceutical biomarkers that play a key role in altering drug concentration levels and determining side effect profiles of drugs.

By characterising these polymorphisms, participants in clinical trials can be differentiated on a genetic basis into those who are likely to benefit from treatment and those who may experience adverse reactions.

The TaqMan Drug Metabolism Genotyping Assays are single-tube probe and primer sets for use on Applied Biosystems Real-Time PCR instruments, including the 7300, 7500, and 7900HT Real-Time PCR Systems.
Advertisement